Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 4/20 | 0.36 |
| ▸ | RAB9A | P51151 | 4/20 | 0.36 |
| ▸ | RET | P07949 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | RAF1 | P04049 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15469304 | 0.83 | ALDH1A1 (0.40) | MEN1KMT2AGRM5ALDH1A1LMNA | |
| SCHEMBL3765590 | 0.83 | MEN1 (0.42) | MEN1KMT2AALDH1A1LMNAEGFR | |
| SCHEMBL26151606 | 0.83 | MEN1 (0.42) | MEN1KMT2AALDH1A1LMNAEGFR | |
| SCHEMBL25796460 | 0.83 | MEN1 (0.42) | MEN1KMT2AALDH1A1LMNAEGFR | |
| SCHEMBL3760684 | 0.83 | KMT2A (0.46) | MEN1KMT2AALDH1A1LMNAEGFR | |
| SCHEMBL24132390 | 0.83 | MEN1 (0.42) | MEN1KMT2AALDH1A1LMNAEGFR | |
| SCHEMBL26152889 | 0.81 | MEN1 (0.43) | MEN1KMT2AALDH1A1LMNAEGFR | |
| SCHEMBL24029388 | 0.81 | GRM5 (0.39) | GRM5ALDH1A1LMNAMAPK14SMN1; SMN2 | |
| SCHEMBL23966715 | 0.80 | MEN1 (0.40) | MEN1KMT2AALDH1A1LMNAEGFR | |
| SCHEMBL12602869 | 0.80 | GRM5 (0.36) | GRM5ALDH1A1LMNASMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| WO-2023217851-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF-κB INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-16 | — | — | WO | disclosed |
| US-20230330249-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | GENENTECH, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| EP-4248975-A2 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | Rigel Pharmaceuticals, Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| US-11713321-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713321-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. | 2023-06-29 | — | — | US | disclosed |
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. | 2023-06-29 | — | — | US | disclosed |
| US-20100063041-A1 | NOVEL PHENYLPROPIONIC ACID DERIVATIVES AS PEROXISOME PROLIFERATOR-ACTIVATED GAMMA RECEPTOR MODULATORS, METHOD OF THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONG-A PHARM. CO., LTD. (KR) | 2010-03-11 | — | — | US | disclosed |
| US-7652051-B2 | Heterocyclic compounds and methods of use | TARGEGEN, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20090023740-A1 | SODIUM CHANNEL INHIBITORS | ICAGEN (US) | 2009-01-22 | — | — | US | disclosed |
| US-20080182837-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-31 | — | — | US | disclosed |
| US-7388021-B2 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-06-17 | — | — | US | disclosed |
| WO-2008003770-A1 | PHENYL SUBSTITUTED HETEROARYL-DERIVATIVES AND USE THEREOF AS ANTI-TUMOR AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-01-10 | — | — | WO | disclosed |
| US-20070232648-A1 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-04 | — | — | US | disclosed |
| US-20070232604-A1 | receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors | AMBIT BIOSCIENCES CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-20070232604-A1 | receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors | AMBIT BIOSCIENCES CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | SCHERING CORPORATION | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | CNR2, GPR119, GLP1R | MEN1 991/4885KMT2A 193/4885GRM5 126/4885 |
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | NEK7, NEK1, NEK5 | MEN1 1800/4885KMT2A 2881/4885GRM5 3408/4885 |
| US-11713321-B2 | Inhibitors of NEK7 kinase | NEK7, NEK1, NEK5 | MEN1 1766/4885KMT2A 2554/4885GRM5 3195/4885 |
| US-20090023740-A1 | SODIUM CHANNEL INHIBITORS | TRPV1, SCN1A, SCN2A | MEN1 4426/4885KMT2A 1945/4885GRM5 284/4885 |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | MEN1 3098/4885KMT2A 4530/4885GRM5 4105/4885 |
| US-12043613-B2 | Inhibitors of SARM1 | SARM1, SMN1; SMN2, SARNP | MEN1 4363/4885KMT2A 3434/4885GRM5 1372/4885 |
| US-20070232648-A1 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD | NR3C1, NR3C2, MC2R | MEN1 3570/4885KMT2A 4084/4885GRM5 177/4885 |
| US-20100063041-A1 | NOVEL PHENYLPROPIONIC ACID DERIVATIVES AS PEROXISOME PROLIFERATOR-ACTIVATED GAMMA RECEPTOR MODULATORS, METHOD OF THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | PPARA, PPARG, PPARD | MEN1 4867/4885KMT2A 2485/4885GRM5 396/4885 |
| US-20230330249-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | ADRM1, CD79B, BRDT | MEN1 4258/4885KMT2A 2759/4885GRM5 1067/4885 |
| US-20070232604-A1 | receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors | GRK2, GRK3, BLK | MEN1 4104/4885KMT2A 2024/4885GRM5 589/4885 |
| US-20080182837-A1 | NEW CHEMICAL COMPOUNDS | CCNA1, CCNT1, MKI67 | MEN1 373/4885KMT2A 2240/4885GRM5 4130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.